# Identification of novel amino acid variants in the Han Chinese population that impair toll-like receptor 4 signaling and confer hyporesponsiveness to lipopolysaccharide

**Authors:** Bin Zhou, Zhaoying Lv, Ruijuan Zu, Jianbo Liu, Yuting Yang, Zongguang Zhou, Yuan Li

PMC · DOI: 10.3389/fimmu.2025.1556600 · Frontiers in Immunology · 2025-10-01

## TL;DR

This study identifies new TLR4 gene variants in Han Chinese people that reduce immune responses to lipopolysaccharide and may lessen severe acute pancreatitis severity.

## Contribution

The study discovers and functionally validates novel TLR4 missense variants in Han Chinese individuals that impair TLR4 signaling and reduce inflammation.

## Key findings

- Five novel TLR4 missense variants were identified in Han Chinese patients with acute pancreatitis.
- Three variants (p.Gly715Ser, p.Arg763Cys, p.Arg804Trp) failed to interact with MyD88 and suppressed NF-κB activation and IL-8 expression.
- Mice with the Tlr4 p.Arg804Trp mutation showed reduced SAP severity, inflammation, and immune cell infiltration compared to wild-type controls.

## Abstract

Severe acute pancreatitis (SAP), characterized by life-threatening inflammation and multiorgan failure, involves Toll-like receptor 4 (TLR4)-mediated hyperinflammation. This study investigates TLR4 variants’ impact on disease severity.

Sanger sequencing was performed in a Han Chinese cohort of patients with acute pancreatitis to screen for TLR4 variants. In silico analyses predicted structural consequences of identified missense variants on protein conformation, transmembrane domains, and isoelectric points. Co-immunoprecipitation assays assessed interactions between wild-type or mutant TLR4 and MyD88 in human embryonic kidney (HEK) 293T cells. Luciferase reporter assays and interleukin 8 (IL-8) expression tests evaluated nuclear factor kappa B (NF-κB) activation and downstream inflammatory signaling. To validate clinical relevance, knock-in mice carrying the Tlr4 p.(Arg804Trp) variant were generated, and SAP models were established to compare histopathological scores, apoptosis, immune cell infiltration, and serum biomarkers (amylase, lipase, IL-6, IL-10, tumor necrosis factor alpha) between homozygous mutant and wild-type controls.

Five novel missense variants in TLR4 were identified in the Han Chinese cohort. In silico analyses predicted subtle alterations to the protein’s secondary structure for all five variants, with p.(Arg763Cys) specifically affecting the transmembrane domain and theoretical isoelectric point. Co-immunoprecipitation revealed that p.(Gly715Ser), p.(Arg763Cys), and p.(Arg804Trp) failed to interact with MyD88. Functional characterization in HEK293T cells confirmed that these three variants suppressed NF-κB activation and downstream IL-8 expression. In knock-in mice, homozygous Tlr4 p.(Arg804Trp) mutants exhibited significantly lower histological scores, reduced apoptosis, decreased neutrophil and macrophage infiltration, and lower serum levels of amylase, lipase, IL-6, and IL-10 compared to wild-type controls.

We characterized novel TLR4 variants that compromise its signaling function, resulting in lipopolysaccharide hyporesponsiveness and attenuated SAP. These findings underscore the significance of genetic determinants in modulating SAP severity and advocate for TLR4-targeted interventions as a promising therapeutic approach.

## Linked entities

- **Genes:** TLR4 (toll like receptor 4) [NCBI Gene 7099], MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576], IL6 (interleukin 6) [NCBI Gene 3569], IL10 (interleukin 10) [NCBI Gene 3586], TNF (tumor necrosis factor) [NCBI Gene 7124], TLR4 (toll like receptor 4) [NCBI Gene 7099]
- **Proteins:** MYD88 (MYD88 innate immune signal transduction adaptor), NFKB1 (nuclear factor kappa B subunit 1), IL8L1 (interleukin 8-like 1), IL6 (interleukin 6), IL10 (interleukin 10)
- **Diseases:** acute pancreatitis (MONDO:0006515)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}
- **Diseases:** acute pancreatitis (MESH:D010195), multiorgan failure (MESH:D051437), inflammation (MESH:D007249), SAP (MESH:D045169)
- **Chemicals:** lipopolysaccharide (MESH:D008070)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Arg804Trp, Arg763Cys, Gly715Ser
- **Cell lines:** 293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HEK — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_M624)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12521208/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12521208/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12521208/full.md

---
Source: https://tomesphere.com/paper/PMC12521208